The Role of Liquid Biopsies in Tracking Tumor Evolution and Overcoming Therapeutic Resistance in Cancer
Open Access
- 8 October 2025
- journal article
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 1 (1) , onmt006
Abstract
Liquid biopsies have developed as a revolutionary technique in cancer diagnosis, treatment evaluation, and the detection of therapeutic resistance. Unlike traditional tissue biopsies, which are invasive and limited to a single temporal analysis, liquid biopsies offer a non-invasive, real-time evaluation of tumour dynamics through the analysis of biomarkers such as circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), exosomes, and microRNAs. This approach enables continuous monitoring of tumour advancement, allowing for the early detection of cancer, the tracking of minimal residual disease, and the identification of emerging resistance mutations. As cancers advance and acquire resistance to therapies, liquid biopsy provides critical information that enables clinicians to customise treatment strategies and improve outcomes. Despite challenges such as sensitivity limitations in early-stage cancers and the necessity for standardised testing protocols, technological advancements, including next-generation sequencing (NGS), CRISPR, and AI-driven analytics, are enhancing the precision and accessibility of liquid biopsies. Through ongoing validation and cost-reduction efforts, liquid biopsies are set to become essential to precision oncology, offering a transformative approach to cancer therapy that could improve patient outcomes and foster equitable healthcare globally.Keywords
This publication has 30 references indexed in Scilit:
- Transforming Cancer Diagnostics: The Emergence of Liquid Biopsy and Epigenetic MarkersMedcomm, 2025
- Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient TreatmentMedcomm, 2025
- Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologynpj Precision Oncology, 2025
- Liquid biopsy in cancer management: Integrating diagnostics and clinical applicationsPractical Laboratory Medicine, 2024
- Liquid biopsy in cancer: current status, challenges and future prospectsSignal Transduction and Targeted Therapy, 2024
- Liquid biopsy for human cancer: cancer screening, monitoring, and treatmentMedcomm, 2024
- Circulating tumour cells for early detection of clinically relevant cancerNature Reviews Clinical Oncology, 2023
- Understanding and targeting resistance mechanisms in cancerMedcomm, 2023
- Circulating tumor cell isolation for cancer diagnosis and prognosisEBioMedicine, 2022
- Circulating tumor cell profiling for precision oncologyMolecular Oncology, 2021